Reading Time: 7 minutesLast month saw the two-year anniversary since the first COVID lockdown in England (the UK) which changed our lives forever – not least because of
Category: Clinical Trials
32nd Symposium: Virtual 32nd Symposium: Virtual Clinical Trials MND Research Research we fund Symposium Treatments
Symposium Spotlight: A closer look at IMODALS clinical trial outcomes
Reading Time: 6 minutesAs the research team are starting to get stuck into planning our next International Symposium on ALS/MND we are taking a look back at some
Reading Time: 5 minutesThis is a guest blog written by Danielle Boyce, DPA, MPH, Executive Director, the Robert Packard Center for ALS Research and Answer ALS Research Program;
Reading Time: 4 minutesResearchers at King’s College London led by Professor Christopher Shaw, are the first in Europe to embark on a clinical trial targeting a specific genetic
Reading Time: 4 minutesThis is blog number 20 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 5 minutesThis is blog number 19 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 4 minutesThis is blog number 18 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 7 minutesGlobal biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in
Reading Time: 3 minutesThis is the first in a series of three blog articles from Session 7 – Perspectives: Lessons from COVID-19 in which we heard from different